Highlights

  • Bioxyne has signed a strategic manufacturing agreement with Aurora Cannabis Inc. (NASDAQ/TSX: ACB), a global leader in medical cannabis.
  • The partnership initially focuses on supplying GMP-certified medicinal cannabis oils to the Australian market.
  • Expansion plans include the manufacture of cannabis vapes for distribution in Australia, the United Kingdom, and Germany.
  • Early purchase orders have already been received for over 20,000 vapes and 5,000 sublingual oil products.
  • The relationship is projected to generate between AUD 3 million and AUD 5 million in production revenue over the next 12 months.

Bioxyne Limited (ASX:BXN) shares edged up 1.59% to AUD 0.064 on 1 April 2026. The move coincided with the announcement that its wholly owned subsidiary, Breathe Life Sciences (BLS), has entered into a major international manufacturing agreement with Canadian-based giant Aurora Cannabis. The stock continues to show immense strength, remaining up 113.33% over the past year as Bioxyne transitions into a globally recognized pharmaceutical-grade manufacturer.

Validation of Pharmaceutical Expertise

The agreement serves as a significant validation of Bioxyne’s Good Manufacturing Practice (GMP) certified capabilities. Under the terms, BLS will produce precision-dosed cannabis formats for Aurora, leveraging its infrastructure in Australia to meet the demands of highly regulated international markets.

Chief Executive Officer Sam Watson noted that this milestone positions the company as a trusted supplier on the world stage, capable of partnering with top-tier industry leaders to deliver scalable, high-quality medical solutions.

Revenue Impact and Product Pipeline

In supplementary information requested by the ASX, Bioxyne revealed that the collaboration is already operational:

  • Initial Orders: Purchase orders have been secured for two product SKUs of oils and over 20,000 vape units destined for Australia and the UK.
  • Diversification: Orders have also been received for two pastille/gummy SKUs, further broadening the production scope.
  • Financial Outlook: The company expects the production volume to result in AUD 3 million to AUD 5 million in revenue over the coming year as the scope of the agreement grows.

The term of the agreement is an initial 12-month rolling term with automatic renewal, providing a long-term foundation for growth in the European and Australian medicinal sectors.

Global Footprint Expansion

Beyond Australia, the partnership targets the high-growth markets of Germany and the United Kingdom. Aurora’s Executive Vice President of Operations, Alex Miller, emphasized that BLS's manufacturing capabilities complement Aurora's scale and commitment to regulatory compliance. With operations already established in Nagoya, Manchester, and Prague, Bioxyne is utilizing this deal to solidify its presence in the global alternative therapeutics market.

What This Means for Investors?

This agreement represents a "coming of age" for Bioxyne's manufacturing arm, BLS. Partnering with a NASDAQ-listed leader like Aurora provides both immediate cash flow—estimated up to AUD 5 million—and immense brand credibility. As the company begins shipping large quantities of vapes and oils to the UK and Germany, investors are watching for the potential expansion into other investigational medicines like Psilocybin and MDMA, where BLS also holds licenses.